CoChat
Sign Up
Cited by 79

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mast cell phenotypes and microvessels in non‐small cell lung cancer and its prognostic significance

Carlini, María José, Dalurzo, Mercedes Corina Liliana, Lastiri, José María, Smith, David Eduardo, Vasallo, Bartolomé Carlos, Puricelli, Lydia Inés, Lauría de Cidre, Lilia Susana·2010·Human Pathology
DOI 10.1016/j.humpath.2009.04.029
Open this paper in CoChat — free account

Abstract

The impact of interstitial inflammatory cells, such as mast cells, and angiogenesis on the prognosis of cancer patients has been reported in many solid tumors, although there is disagreement about their role. We undertook a retrospective study with tissue samples from 65 patients with stage I and II non-small cell lung cancer to assess the clinical pathologic role and prognostic significance of mast cells. Mast cell phenotypes were identified by immunohistochemistry for tryptase and chymase. In addition, we identified microvessels using the endothelial marker CD34. Mast cell and microvessel density was quantified by assessing immunopositive cells in the intratumoral and peritumoral zones of tumor specimens. Both mast cell and microvessel density was higher in the peritumoral zone than the intratumoral zone (P <or= .05). A positive correlation between mast cell (tryptase-chymase phenotype) and microvessel densities was observed in the intratumoral zone (P <or= .05), supporting the involvement of mast cells in the angiogenic process. Regarding survival, a subset of stage I patients had a worse prognosis at five years when low mast cell (tryptase-chymase phenotype) density was found in the peritumoral zone (median survival in months [range]: 27 [1-60] versus 46 [1-60]). Multivariate Cox analysis indicated that this parameter may be an independent prognostic factor (P <or= .05) useful for selecting candidates for earlier treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.humpath.2009.04.029

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

  • Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis

    Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946 · cited 2×

    “For example, when inducing squamous epithelial carcinogenesis in these mice, neoplastic growth was attenuated in comparison to MCproficient littermates, mostly by a lower activation of the angiogenic vasculature and a failure of keratinocytes to reach hyperproliferative growth characteristics [32].”
    Background

Show all 1 references

Research works printed but not linked: 31

  1. Mueller, 2004, Friends or foes. Bipolar effects of the tumour stroma in cancer, Nature, 4, 839
  2. Ribatti, 2003, Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma, Eur J Clin Invest, 33, 420, 10.1046/j.1365-2362.2003.01152.x · DOI
  3. Mauro, 2008, Association between mast cells of different phenotypes and angiogenesis in colorectal cancer, Mol Med Rep, 1, 8
  4. Kankkunen, 1997, Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions, Int J Cancer, 72, 385, 10.1002/(SICI)1097-0215(19970729)72:3<385::AID-IJC1>3.0.CO;2-L · DOI
  5. Imada, 2000, Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma, Eur Respir J, 15, 1087, 10.1034/j.1399-3003.2000.01517.x · DOI
  6. Takanami, 2000, Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma, Cancer, 88, 2686, 10.1002/1097-0142(20000615)88:12<2686::AID-CNCR6>3.0.CO;2-6 · DOI
  7. Hallgren, 2006, Biology of mast cell tryptase. An inflammatory mediator, FEBS J, 273, 1871, 10.1111/j.1742-4658.2006.05211.x · DOI
  8. Blair, 1997, Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor, J Clin Invest, 99, 2691, 10.1172/JCI119458 · DOI
  9. He, 1997, Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine, J Immunol, 159, 6216, 10.4049/jimmunol.159.12.6216 · DOI
  10. Kaminska, 1999, Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase, J Invest Dermatol, 113, 567, 10.1046/j.1523-1747.1999.00738.x · DOI
  11. Yoshii, 2005, Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners, J Pharmacol Sci, 98, 450, 10.1254/jphs.FPJ05002X · DOI
  12. Muramatsu, 2000, Chymase mediates mast cell-induced angiogenesis in hamster sponge granulomas, Eur J Pharm, 402, 181, 10.1016/S0014-2999(00)00350-2 · DOI
  13. Fang, 1997, Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain, J Biol Chem, 272, 25628, 10.1074/jbc.272.41.25628 · DOI
  14. Theoharides, 2004, Mast cells: the Jekyll and Hyde of tumor growth, Trends Immunol, 25, 235, 10.1016/j.it.2004.02.013 · DOI
  15. Norrby, 2002, Mast cells and angiogenesis, APMIS, 110, 355, 10.1034/j.1600-0463.2002.100501.x · DOI
  16. Ibaraki, 2005, The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non–small cell lung cancer, Eur J Cardiothorac Surg, 28, 617, 10.1016/j.ejcts.2005.06.020 · DOI
  17. Tomita, 2000, Effect of mast cells on tumor angiogenesis in lung cancer, Ann Thorac Surg, 69, 1686, 10.1016/S0003-4975(00)01160-7 · DOI
  18. Welsh, 2005, Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non–small-cell lung cancer, J Clin Oncol, 23, 8959, 10.1200/JCO.2005.01.4910 · DOI
  19. Tomita, 1999, Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma, Lung Cancer, 26, 103, 10.1016/S0169-5002(99)00076-8 · DOI
  20. Irani, 1989, Mast cell heterogeneity, Clin Exp Allergy, 19, 143, 10.1111/j.1365-2222.1989.tb02357.x · DOI
  21. Cabanillas-Saez, 2002, Characterization of mast cells according to their content of tryptase and chymase in normal and neoplastic human uterine cervix, Int J Gynecol Cancer, 12, 92, 10.1046/j.1525-1438.2002.01082.x · DOI
  22. Nagata, 2003, Chymase-positive mast cells in small sized adenocarcinoma of the lung, Virchows Arch, 443, 565, 10.1007/s00428-003-0842-y · DOI
  23. Rajput, 2008, Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases, Breast Cancer Res Treat, 107, 249, 10.1007/s10549-007-9546-3 · DOI
  24. Nielsen, 1999, Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue, J Pathol, 189, 487, 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I · DOI
  25. Tataroglu, 2004, Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC), Lung Cancer, 43, 47, 10.1016/j.lungcan.2003.08.013 · DOI
  26. Dundar, 2008, The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma, J Int Med Res, 36, 88, 10.1177/147323000803600112 · DOI
  27. Nienartowicz, 2006, Mast cells in neoangiogenesis, Med Sci Monit, 12, RA53
  28. Folkman, 1992, Control of angiogenesis by heparin and other sulfated polysaccharides, Adv Exp Med Biol, 313, 355, 10.1007/978-1-4899-2444-5_34 · DOI
  29. Powers, 2000, Fibroblast growth factors, their receptors and signaling, Endocr Relat Cancer, 7, 165, 10.1677/erc.0.0070165 · DOI · Paper page
  30. Stack, 1994, Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase), J Biol Chem, 269, 9416, 10.1016/S0021-9258(17)36896-5 · DOI
  31. de Visser, 2006, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, 6, 24, 10.1038/nrc1782 · DOI

Cited by

Sorted by citations

Metadata

Authors
Carlini, M. J., Dalurzo, M. C. L., Lastiri, J. M., Smith, D. E., Vasallo, B. C., Puricelli, L. I., & Lauría de Cidre, L. S.
Venue
Human Pathology
Publisher
Elsevier BV
Published
2010-05
Volume
41
Issue
5
Pages
697-705
ISSN
0046-8177
DOI
10.1016/j.humpath.2009.04.029
Cited by
79
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review